Cargando…
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort study to compare composite complete remission (CCR)...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008336/ https://www.ncbi.nlm.nih.gov/pubmed/35433414 http://dx.doi.org/10.3389/fonc.2022.858202 |
_version_ | 1784687029818228736 |
---|---|
author | Mustafa Ali, Moaath K. Corley, Elizabeth M. Alharthy, Hanan Kline, Kathryn A. F. Law, Jennie Y. Lee, Seung Tae Niyongere, Sandrine Duong, Vu H. Emadi, Ashkan Baer, Maria R. |
author_facet | Mustafa Ali, Moaath K. Corley, Elizabeth M. Alharthy, Hanan Kline, Kathryn A. F. Law, Jennie Y. Lee, Seung Tae Niyongere, Sandrine Duong, Vu H. Emadi, Ashkan Baer, Maria R. |
author_sort | Mustafa Ali, Moaath K. |
collection | PubMed |
description | There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort study to compare composite complete remission (CCR) rates, median overall survival (m-OS) and median event-free survival (m-EFS). A total of 170 adult AML patients were treated with first-line azacitidine (AZA) or decitabine (DEC) +/- VEN. Median age was 71 years and 99 (58%) were male. Median follow-up in HMA and HMA-VEN groups was 79 and 21 months. Treatments included AZA alone (n=35, 21%), DEC alone (n=84, 49%), AZA-VEN (n=24, 14%) and DEC-VEN (n=27, 16%). VEN improved CCR rates to HMAs overall (52% vs. 27%, P<0.05) and to AZA (54% vs. 10%, P<0.05), but not to DEC (43% vs. 32%, P=0.35); it did not improve OS, and only improved EFS for AZA (10.5 vs. 3.8 months, P<0.05). CCR rates were lower with AZA than with DEC (13% vs. 33%, P<0.05), but OS and EFS were not different statistically. CCR rates did not differ for AZA-VEN vs. DEC-VEN (CCR: 58% vs. 52%, P=0.66), but OS and EFS were longer for AZA-VEN (m-OS: 12.3 vs. 2.2 months, P<0.05; m-EFS: 9.2 vs. 2.1 months, P<0.05). Our analysis showed that combining VEN with AZA in newly diagnosed AML patients improved outcomes, but combining VEN with DEC did not. AZA-VEN was associated with improved outcomes compared to DEC-VEN. Further studies are needed to test the benefit of combining VEN with DEC. |
format | Online Article Text |
id | pubmed-9008336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90083362022-04-15 Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study Mustafa Ali, Moaath K. Corley, Elizabeth M. Alharthy, Hanan Kline, Kathryn A. F. Law, Jennie Y. Lee, Seung Tae Niyongere, Sandrine Duong, Vu H. Emadi, Ashkan Baer, Maria R. Front Oncol Oncology There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort study to compare composite complete remission (CCR) rates, median overall survival (m-OS) and median event-free survival (m-EFS). A total of 170 adult AML patients were treated with first-line azacitidine (AZA) or decitabine (DEC) +/- VEN. Median age was 71 years and 99 (58%) were male. Median follow-up in HMA and HMA-VEN groups was 79 and 21 months. Treatments included AZA alone (n=35, 21%), DEC alone (n=84, 49%), AZA-VEN (n=24, 14%) and DEC-VEN (n=27, 16%). VEN improved CCR rates to HMAs overall (52% vs. 27%, P<0.05) and to AZA (54% vs. 10%, P<0.05), but not to DEC (43% vs. 32%, P=0.35); it did not improve OS, and only improved EFS for AZA (10.5 vs. 3.8 months, P<0.05). CCR rates were lower with AZA than with DEC (13% vs. 33%, P<0.05), but OS and EFS were not different statistically. CCR rates did not differ for AZA-VEN vs. DEC-VEN (CCR: 58% vs. 52%, P=0.66), but OS and EFS were longer for AZA-VEN (m-OS: 12.3 vs. 2.2 months, P<0.05; m-EFS: 9.2 vs. 2.1 months, P<0.05). Our analysis showed that combining VEN with AZA in newly diagnosed AML patients improved outcomes, but combining VEN with DEC did not. AZA-VEN was associated with improved outcomes compared to DEC-VEN. Further studies are needed to test the benefit of combining VEN with DEC. Frontiers Media S.A. 2022-03-31 /pmc/articles/PMC9008336/ /pubmed/35433414 http://dx.doi.org/10.3389/fonc.2022.858202 Text en Copyright © 2022 Mustafa Ali, Corley, Alharthy, Kline, Law, Lee, Niyongere, Duong, Emadi and Baer https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Mustafa Ali, Moaath K. Corley, Elizabeth M. Alharthy, Hanan Kline, Kathryn A. F. Law, Jennie Y. Lee, Seung Tae Niyongere, Sandrine Duong, Vu H. Emadi, Ashkan Baer, Maria R. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study |
title | Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study |
title_full | Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study |
title_fullStr | Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study |
title_full_unstemmed | Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study |
title_short | Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study |
title_sort | outcomes of newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: a propensity score-adjusted cohort study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008336/ https://www.ncbi.nlm.nih.gov/pubmed/35433414 http://dx.doi.org/10.3389/fonc.2022.858202 |
work_keys_str_mv | AT mustafaalimoaathk outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT corleyelizabethm outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT alharthyhanan outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT klinekathrynaf outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT lawjenniey outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT leeseungtae outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT niyongeresandrine outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT duongvuh outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT emadiashkan outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy AT baermariar outcomesofnewlydiagnosedacutemyeloidleukemiapatientstreatedwithhypomethylatingagentswithorwithoutvenetoclaxapropensityscoreadjustedcohortstudy |